Novogen Limited sinks 30%: Here's why

Novogen Limited (ASX:NRT) sinks on huge capital raising and rights issue

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotech stock Novogen Limited (ASX: NRT) has seen its shares fall more than 30% today after the company announced plans to issue 98.7 million new shares at 30 cents each.

In lunchtime trading, Novogen shares were changing hands at around 28 cents. That suggests that shareholders aren't happy to be in the company and are selling down no matter the price. Theoretically, shares should only have dropped as low as 30 cents – the price at which new shares are being issued.

Either that or investors see the strong chance of further dilution taking place thanks to the issue of options for another 147 million shares. Novogen is issuing 6-month options up to 98 million ordinary shares at 30 cents and 5-year options over a further 49 million ordinary shares at a price of 40 cents.

The biotech is raising $15.5 million in a private placement to institutional investors, with a further $15 million expected to be raised via a 1 for 6 non-renounceable rights issue to existing shareholders.

Novogen says it needs the funds to 'provide a runway for our 3 lead oncology candidate drugs', 'where we might expect to see objective evidence of clinical benefit.'

Despite today's fall, shares in Novogen are still 155% higher than at the start of this year, following a number of positive announcement surrounding its anti-cancer drugs – as colleague Ryan Newman pointed out last week.

But as I often note when writing about investing in small biotech stocks, the huge risks mean investors can and need to take some precautions against one or more biotech stocks in their portfolio from crashing.

And that happens on a regular basis. Check out the charts for Pharmaxis Ltd (ASX: PXS), Prana Biotechnology Limited (ASX: PBT), QRxPharma Ltd (ASX: QRX) and Acrux Limited (ASX: ACR) – which all look like rollercoasters and you can see what I mean.

Very few end up hugely successful like CSL Limited (ASX: CSL), Resmed Inc (ASX: RMD) and Cochlear Limited (ASX: COH).

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. Motley Fool writer/analyst Mike King owns shares in CSL, Cochlear and Resmed. You can follow Mike on Twitter @TMFKinga

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »